Related Experiment Video

Updated: Mar 9, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Tumour immunology: NLRC3 inhibits mTOR in colorectal cancer

Olive Leavy

    Nature Reviews. Immunology
    |January 4, 2017
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
    06:24

    Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

    Published on: October 13, 2023

    1.7K
    SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry
    10:16

    SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry

    Published on: January 6, 2017

    7.7K

    Related Experiment Videos

    Last Updated: Mar 9, 2026

    Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
    06:51

    Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

    Published on: July 21, 2018

    18.8K
    Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
    06:24

    Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

    Published on: October 13, 2023

    1.7K
    SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry
    10:16

    SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry

    Published on: January 6, 2017

    7.7K

    Related Concept Videos

    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    5.0K
    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    5.0K
    PI3K/mTOR/AKT Signaling Pathway01:22

    PI3K/mTOR/AKT Signaling Pathway

    6.1K
    The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
    6.1K

    Articles linked to this work by shared authors, journal, and citation graph.

    LAG3 checkpoint function and its mechanism of action in therapeutic targeting.

    Nature reviews. Immunology·2026

    A guide to B cell metabolism.

    Nature reviews. Immunology·2026

    The effects of IFNγ on tissue physiology through structural cells.

    Nature reviews. Immunology·2026

    Plasticity of the infant immune system during the perinatal period.

    Nature reviews. Immunology·2026

    Immunogenic cell death and tertiary lymphoid structures: bridging tumour cell death and immune organization.

    Nature reviews. Immunology·2026

    Interleukin-33 and its receptor: multifaceted roles and emerging therapeutic potential.

    Nature reviews. Immunology·2026

    Senomorphic miR-3155b suppresses the senescence-associated secretory phenotype in therapy-induced senescence.

    Frontiers in cell and developmental biology·2026

    Predictive biomarkers for precision treatment in rheumatoid arthritis: are we there yet?

    Frontiers in pharmacology·2026

    Breaking the ERK1/2 negative feedback loop: avoiding reactivation and acquisition of resistance by ERK1/2 to anti-cancer agents.

    Frontiers in oncology·2026

    Clinical trial landscape and translational priorities for adoptive T-cell and NK-cell therapies in gynecologic malignancies.

    Frontiers in immunology·2026

    Oncolytic reovirus: tumor-microenvironment remodeling, engineering constraints, and translational strategies.

    Frontiers in immunology·2026

    Profiling crystal engineered ligands for targeting treatment resistant androgen receptors.

    Frontiers in pharmacology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us